Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


Decoding therapy resistance in liver tumours: a giant leap

This article has been updated

In 2021, our understanding of resistance to therapy in primary liver tumours improved drastically. By taking a holistic approach, three independent studies have characterized the tumour cell biodiversity across space, time and aetiologies in primary liver cancer, decoding the crosstalk between different cell types within the tumour ecosystem and their individual contributions to therapy resistance.

Key advances

  • Integrated genomic analysis discovered a major role for cell plasticity in the spatio-temporal evolution of paediatric liver cancers and their resistance to cisplatin-based chemotherapy3.

  • Single-cell transcriptomic profiling of primary liver tumours (hepatocellular carcinoma and intra-hepatic cholangiocarcinoma) identified intra-tumoural cell states and quantified the degree of diversity, which could help to understand tumour evolution in response to treatment4.

  • Anti-PD1 treatment can accelerate hepatocarcinogenesis or be ineffective in the context of nonalcoholic steatohepatitis, which highlights a potential weakness of immunotherapies6.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Fig. 1: Liver heterogeneity and resistance to therapy.

Change history

  • 12 November 2021

    The article strapline (Liver cancer in 2021) was missing and this has now been corrected online.


  1. 1.

    Villanueva, A. Hepatocellular carcinoma. N. Engl. J. Med. 380, 1450–1462 (2019).

    CAS  Article  Google Scholar 

  2. 2.

    Boumahdi, S. & de Sauvage, F. J. The great escape: tumour cell plasticity in resistance to targeted therapy. Nat. Rev. Drug. Discov. 19, 39–56 (2020).

    CAS  Article  Google Scholar 

  3. 3.

    Hirsch, T. Z. et al. Integrated genomic analysis identifies driver genes and cisplatin-resistant progenitor phenotype in pediatric liver cancer. Cancer Discov. (2021).

    Article  PubMed  Google Scholar 

  4. 4.

    Ma, L. et al. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J. Hepatol. (2021).

    Article  PubMed  Google Scholar 

  5. 5.

    Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).

    Article  Google Scholar 

  6. 6.

    Pfister, D. et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 592, 450–456 (2021).

    CAS  Article  Google Scholar 

  7. 7.

    Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O. & Heikenwalder, M. From NASH to HCC: current concepts and future challenges. Nat. Rev. Gastroenterol. Hepatol. 16, 411–428 (2019).

    Article  Google Scholar 

  8. 8.

    Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 7, 6 (2021).

    Article  Google Scholar 

Download references

Author information



Corresponding author

Correspondence to Amaia Lujambio.

Ethics declarations

Competing interests

A.L. has received consulting fees from AstraZeneca and research funding from Genentech and Pfizer. C.D. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Desdouets, C., Lujambio, A. Decoding therapy resistance in liver tumours: a giant leap. Nat Rev Gastroenterol Hepatol 19, 83–84 (2022).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing